Images List Premium Download Classic

Psychiatric Disorders

Psychiatric Disorders-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
5-ht3 receptor antagonists
September 14, 2017 - N°20170260201

Which are useful for the treatment of diseases treatable by inhibition of 5-ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Methyl oxazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
September 14, 2017 - N°20170260177

The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Heteroaryl orexin receptor antagonists
Merck Sharp & Dohme Corp.
September 14, 2017 - N°20170260136

The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention ...
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Transgenic mouse model for conditional fkbp51 expression and related methods
University Of South Florida
September 14, 2017 - N°20170258940

The subject invention pertains to transgenic non-human animals comprising a transgenic nucleotide sequence, integrated into the genome of the animals, comprising a nucleotide sequence encoding human fkbp51 operably linked to a tetracycline response element. In some embodiments, the transgenic animal comprises an additional transgenic nucleotide sequence, integrated into the genome of the animal, comprising a nucleotide sequence encoding a tetracycline ...
Ester of a phospholipid with conjugated linoleic acid for the treatment of psychiatric disorders with ...
Universita' Degli Studi Di Cagliari
September 14, 2017 - N°20170258924

An ester of a phospholipid with conjugated linoleic acid for use in the therapeutic treatment of or as a food supplement for psychiatric disorders with neuroinflammatory and neurodegenerative basis, such as depression and schizophrenia.
Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
Prexton Therapeutics Sa
September 07, 2017 - N°20170253613

The present invention provides a novel chromone oxime derivative of formula (i), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic ...
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Amphiphilic compounds with neuroprotective properties
Fyziologicky Ustav Av Cr, V.v.i.
August 24, 2017 - N°20170240588

Amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use in methods of treatment of neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of cns, neurodegenerative changes and disorders of cns, affective disorders, depression, post-traumatic stress disorder and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, ...
(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2...
Bristol-myers Squibb Company
August 03, 2017 - N°20170216325

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system.
Therapeutic isoxazole compounds
Bristol-myers Squibb Company
July 20, 2017 - N°20170204111

Wherein a1, a2, a3, r1, x, y, and b have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase b (mao-b) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders ...
Allosteric modulators of cb1 cannabinoid receptors
Northeastern University
July 13, 2017 - N°20170197918

The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (cb1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the cb1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of ...
2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and ...
Northeastern University
July 06, 2017 - N°20170190678

Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
Method of treatment of schizophreniform disorder
Curemark, Llc
July 06, 2017 - N°20170189501

Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of ...
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
July 06, 2017 - N°20170189358

Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e. G., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic ...
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Merck Patentgesellschaft
June 29, 2017 - N°20170182037

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid ...
Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors
Merck Patentgesellschaft
June 29, 2017 - N°20170182011

Their use as allosteric modulators of mglur5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
June 29, 2017 - N°20170181989

Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e. G., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic ...
Exo-s-mecamylamine formulation and use in treatment
University Of South Florida
June 29, 2017 - N°20170181983

A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0. 5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-r-mecamylamine, said ...
Botulinum toxin treatments of neurological and neuropsychiatric disorders
Allergan, Inc.
June 22, 2017 - N°20170173123

Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/...
Methods for diagnosing and treating neuroimmune-based psychiatric disorders
The Regents Of The University Of California
June 15, 2017 - N°20170166968

The methods of the present invention are useful for determining whether an individual has or is at risk of developing a neuroimmune-based psychiatric disorder by detecting the expression level of one or more cytokine receptors in a biological sample. The methods of the present invention are also useful for the in vivo imaging of brain tissue by detecting one or ...
Mecp2e1 gene
Centre For Addiction And Metal Health
June 01, 2017 - N°20170152564

The invention is a novel mecp2e1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring ...
Centre For Addiction And Metal Health
May 25, 2017 - N°20170143959

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or ...
Loading